SCHEMBL773152

SCHEMBL773152

O=c1c(O)c(-c2cccc3ccccc23)oc2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NMUR2 Q9GZQ4 4/20 0.68
KDM4E B2RXH2 10/20 0.64
MEN1 O00255 9/20 0.64
KMT2A Q03164 9/20 0.64
CYP3A4 P08684 8/20 0.64
TP53 P04637 6/20 0.64
MAPK1 P28482 5/20 0.64
ALOX15 P16050 4/20 0.64
LMNA P02545 3/20 0.64
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
ABCB1 P08183 1/20 0.64
CALM1 P0DP23 1/20 0.64
AR P10275 1/20 0.64
PKM P14618 1/20 0.64
CYP1B1 Q16678 1/20 0.64
CA9 Q16790 1/20 0.64
HSD17B10 Q99714 6/20 0.62
ALDH1A1 P00352 5/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17786435 0.84 KMT2A (0.50) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL471860 0.84 NMUR2 (0.68) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL31675811 0.83 NMUR2 (0.71) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL290080 0.83 NMUR2 (0.71) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL1421375 0.83 NMUR2 (0.62) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL16586869 0.81 NMUR2 (0.68) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL15676117 0.81 NMUR2 (0.68) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL6095363 0.80 NTRK1 (0.63) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL3062193 0.80 KDM4E (0.72) NMUR2KDM4EMEN1KMT2ACYP3A4
SCHEMBL2746872 0.80 MEN1 (0.90) NMUR2KDM4EMEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7211414-B2 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity VISIGEN BIOTECHNOLOGIES, INC. (US) 2007-05-01 US claimed
EP-3415641-B1 METHOD FOR ANALYSIS OF MOLECULES PACIFIC BIOSCIENCES CALIFORNIA INC (US) 2023-11-01 EP disclosed
EP-3415641-A1 METHOD FOR ANALYSIS OF MOLECULES Pacific Biosciences Of California, Inc. (US) 2018-12-19 EP disclosed
US-20180100191-A1 ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS VISIGEN BIOTECHNOLOGIES, INC. 2018-04-12 US disclosed
US-9845500-B2 Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis Life Technologies Corporation (US) 2017-12-19 US disclosed
US-20170343479-A1 APPARATUS AND METHOD FOR PERFORMING NUCLEIC ACID ANALYSIS PACIFIC BIOSCIENCES CALIFORNIA INC (US) 2017-11-30 US disclosed
US-9709503-B2 Apparatus and method for performing nucleic acid analysis PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2017-07-18 US disclosed
US-9588051-B2 Apparatus and method for performing nucleic acid analysis PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2017-03-07 US disclosed
US-20170002409-A1 APPARATUS AND METHOD FOR PERFORMING NUCLEIC ACID ANALYSIS PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2017-01-05 US disclosed
US-20160244822-A1 ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS Life Technologies Corporation 2016-08-25 US disclosed
US-20060061755-A1 Apparatus and method for analysis of molecules PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2006-03-23 US disclosed
US-20060061754-A1 Arrays of optical confinements and uses thereof PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2006-03-23 US disclosed
US-20060063264-A1 Apparatus and method for performing nucleic acid analysis PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2006-03-23 US disclosed
US-20060062531-A1 Fabrication of optical confinements PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2006-03-23 US disclosed
EP-1354064-A2 ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY Visigen Biotechnologies, Inc. (US) 2003-10-22 EP disclosed
US-20030134807-A1 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity Life Technologies Corporation 2003-07-17 US disclosed
WO-2002044425-A2 ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY VISIGEN BIOTECHNOLOGIES, INC. (US) 2002-06-06 WO disclosed
US-6399335-B1 MIXING POLYMERASE AND NUCLEOSIDE TRIPHOSPHATE HAVING A GAMMA PHOSPHATE PHOSPHOESTER-LINKED FUNCTIONAL GROUP, INCUBATING SO THAT POLYMERASE CATALYZES CLEAVAGE BETWEEN ALPHA AND BETA PHOSPHATES AND LIBERATES PYROPHOSPHATE WITH FUNCTIONAL GROUP ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. 2002-06-04 US disclosed
US-5552551-A COLORS FOR PHOSPHORESCENCE FLORIDA STATE UNIVERSITY (US) 1996-09-03 US disclosed
WO-1995003343-A1 PROTON-TRANSFER, LOW SELF-ABSORBING CHROMOPHORES FOR USE IN SCINTILLATORS FLORIDA STATE UNIVERSITY (US) 1995-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180100191-A1 ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS RNGTT, PPA1, PNP NMUR2 3860/4885KDM4E 2933/4885MEN1 3457/4885
US-20030134807-A1 Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity RNGTT, PNP, MTAP NMUR2 3477/4885KDM4E 2908/4885MEN1 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.